<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03085394</url>
  </required_header>
  <id_info>
    <org_study_id>SMC-17-3846</org_study_id>
    <nct_id>NCT03085394</nct_id>
  </id_info>
  <brief_title>Preoperative Hexakapron Reduces Bleeding in Bariatric Surgery</brief_title>
  <acronym>PHORBBS</acronym>
  <official_title>Preoperative Hexakapron Reduces Bleeding in Bariatric Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prophylactic use of tranexamic acid to reduce intra and postoperative bleeding in primary
      sleeve gastrectomy procedures will be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients scheduled for primary laparoscopic sleeve gastrectomy for the treatment of morbid
      obesity will be assigned to receive tranexamic acid vs. placebo before surgery.
      Intraoperative bleeding will be scored, as well as postoperative bleeding and blood or
      blood-product requirements. POstoperative venous thromboembolic events will be recorded up to
      2 months following surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment efficiency (lowering/preventing clinically significant bleeding)</measure>
    <time_frame>1 week</time_frame>
    <description>The efficiency of preoperative tranexamic acid administration in lowering/preventing clinically significant bleeding.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment safety (administering tranexamic acid preoperatively without promoting thromboembolic events)</measure>
    <time_frame>2 months</time_frame>
    <description>The safety of administering tranexamic acid preoperatively without promoting thromboembolic events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for reintervention</measure>
    <time_frame>1 week</time_frame>
    <description>The proportion of patients requiring invasive intervention (percutaneous/operative) due to bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure change</measure>
    <time_frame>1 day</time_frame>
    <description>The proportion of patients requiring alteration of intended procedure due to bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood/blood product requirement</measure>
    <time_frame>1 week</time_frame>
    <description>The usage of blood/blood products after surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Intra-Operative Injury - Other</condition>
  <condition>Post Operative Hemorrhage</condition>
  <condition>Tranexamic Acid</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preoperative intravenous administration of 2g tranexamic acid in 10ml fluid.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Preoperative intravenous administration of 10ml normal saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tranexamic acid</intervention_name>
    <description>Preoperative intravenous administration of 2 grams tranexamic acid in 10 ml saline</description>
    <arm_group_label>Treatment arm</arm_group_label>
    <other_name>Hexakapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Preoperative intravenous administration of 10 ml saline</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Morbid obesity

          -  Approved and scheduled for laparoscopic sleeve gastrectomy

        Exclusion Criteria:

          -  Previous bariatric surgery

          -  Platelet count under 100,000

          -  Concurrent anticoagulation treatment

          -  Previous venous/atrerial thromboembolic event

          -  Known allergy to tranexamic acid

          -  History of heparin induced thrombocytopenia

          -  Oral contraceptive use

          -  Female hormonal replacement therapy

          -  Active thromboembolic state

          -  Genetic hypercoagulable state
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Goitein, MD</last_name>
    <phone>+97235302714</phone>
    <email>david.goitein@sheba.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aharon Lubetsky, MD</last_name>
    <phone>+97235302120</phone>
    <email>Aharon.Lubetsky@sheba.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Goitein, MD</last_name>
      <phone>+97235302714</phone>
      <email>david.goitein@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>David Goitein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aharon Lubetski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2017</study_first_posted>
  <last_update_submitted>October 6, 2017</last_update_submitted>
  <last_update_submitted_qc>October 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>David Goitein MD</investigator_full_name>
    <investigator_title>Head, Bariatric and Metabolic Surgery</investigator_title>
  </responsible_party>
  <keyword>Morbid Obesity</keyword>
  <keyword>Sleeve gastrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

